Zoledronic Acid in the Management of Patients With Asymptomatic/Early Stage Multiple Myeloma
Multiple Myeloma
About this trial
This is an interventional prevention trial for Multiple Myeloma focused on measuring Multiple Myeloma, Bisphosphonates
Eligibility Criteria
Inclusion Criteria: Diagnosis of asymptomatic multiple myeloma as defined by the criteria below: Presence of bone marrow clonal plasma cells (more than 10%) Presence of an M-protein in serum and/or urine (no concentration specified) Serum calcium < 12 mg/dl within 14 days prior to registration. Less than 3 lytic lesions, no pathologic fractures and no osteopenia noted on skeletal survey No symptoms of hyperviscosity, amyloidosis or recurrent infection Bone mineral density with a T score higher than -2.0 standard deviation (not have osteoporosis) within 28 days prior to registration Negative pregnancy test Exclusion Criteria: No previous treatment with bisphosphonates No disorders of the parathyroid or thyroid glands No current breastfeeding No prior malignancy is allowed except for adequately treated in situ cervical cancer, Gleason < grade 7 prostate cancers
Sites / Locations
- Elkhart Clinic
- Oncology Hematology Associates of SW Indiana
- Indiana University Cancer Center
- Quality Cancer Center (MCGOP)
- Arnett Cancer Care
- Northern Indiana Cancer Research Consortium
- Providence Medical Group
- AP&S Clinic
Arms of the Study
Arm 1
Arm 2
Active Comparator
No Intervention
A
B
Patients will be randomly assigned by study number to receive 4mg of zoledronic acid every three months.
Patients will be randomly assigned by study number to observation only.